Log in
Enquire now
‌

US Patent 7820666 Tetrahydrotriazolopyrazine derivatives and uses thereof

Patent 7820666 was granted and assigned to Concert Pharmaceuticals on October, 2010 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Concert Pharmaceuticals
Concert Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
78206660
Patent Inventor Names
Scott L. Harbeson0
Date of Patent
October 26, 2010
0
Patent Application Number
121164750
Date Filed
May 7, 2008
0
Patent Citations Received
‌
US Patent 11877591 Device for transferring rod articles used in the tobacco industry
0
Patent Primary Examiner
‌
James O. Wilson
0
Patent abstract

This invention relates to novel substituted tetrahydrotriazolopyrazines and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an enzyme inhibitor of dipeptidyl-peptidase IV (DPP-IV).

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7820666 Tetrahydrotriazolopyrazine derivatives and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.